Abstract Library

#4222 Quali-NET: A prospective study on patient-reported quality of life in neuroendocrine neoplasms

Introduction: Neuroendocrine neoplasms of the lung (LNEN) or gastro-enteropancreatic tract (GEPNEN) are typically slow-growing, leading to longer overall survival, and resembling chronic illnesses. Therefore, focus on quality of life (QoL) is crucial. While brief studies have been done, comprehensive, long-term studies are needed.

Conference:

Presenting Author: Islam O

Authors: Islam O, Depauw L, van der Massen I, Simoens M, Galdermans D,

Keywords: GEP-NEN, LNEN, Quality of life, Longitudinal data,

#4013 A phase 3 randomised study of 177Lu-edotreotide or everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin (LEVEL, GETNE-T2217)

Introduction: Retrospective data for peptide receptor radionuclide therapy (PRRT) have demonstrated promising activity in somatostatin receptor (SSTR)-positive lung neuroendocrine tumors (NETs).

Conference:

Presenting Author:

Authors: García-Álvarez A, Garcia-Carbonero R, Anido U, Jimenez-Fonseca P, Del Olmo-García M,

Keywords: Lung NET, Peptide receptor radionuclide therapy,

#3455 Phase 1 study of Intralesional (IL) rose bengal (PV-10), an investigational autolytic immunotherapy

Introduction: Intralesional (IL) rose bengal (PV-10) is an investigational autolytic immunotherapy.

Conference:

Presenting Author:

Authors: Price T, Cehic G, Watcher E, Sebbon R, Neuhaus S,

Keywords: PV-10, immunotherapy, phase 1,

#3415 The PEI-Q paradox: Qualitative assessment of exocrine function in NET patients treated with SSAs

Introduction: Somatostatin-analogues (SSAs) are first-line treatment of unresectable, symptomatic neuroendocrine tumors (NETs), though can cause pancreatic exocrine insufficiency (PEI). PEI symptoms of diarrhoea, bloating, and steatorrhea overlap with those of NETs (carcinoid sequelae), and both have a negative impact on quality of life. The Pancreatic Exocrine Insufficiency Questionnaire (PEI-Q) can be used to assess PEI; however, we hypothesise that the score will be unreliable in SSA-induced PEI due to concurrent improvement of carcinoid symptoms.

Conference:

Presenting Author: Hall L

Authors: Hall L, Powell-Brett S, Thompson O, Bradley E, Smith S,

Keywords: Pancreatic Exocrine Insufficiency (PEI), Neuroendocrine Tumor (NET), Patient Reported Outcome,

#3389 COMPOSE: Phase III trial of 177Lu-edotreotide versus standard of care in well-differentiated (WD) aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Introduction: Therapeutic algorithm for well-differentiated (WD) high-grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors (G2 + G3 GEP-NETs) is not well established. Current ‘best standard of care’ include CAPTEM, FOLFOX and everolimus. Peptide Receptor Radionuclide Therapy (PRRT) could be useful in high grade NETs, however there is a lack of prospective evidence. 177Lu-edotreotide is an innovative radiolabeled somatostatin analogue with a favourable safety profile and efficacy. The ongoing Phase III trial COMPETE in G1 and G2 GEP-NETs is exploring the efficacy and safety of 177Lu-edotreotide, in comparison to everolimus.

Conference:

Presenting Author:

Authors: Hernando J, Halfdarnarson T, Halperin D, Reidy-Lagunes D, Kong G,

Keywords: neuroendocrine, NET, 177Lu-edotreotide, PRRT,